Hospira (HSP) Tops Q2 EPS by 5c

Hospira (NYSE: HSP) reported Q2 EPS of $0.85, $0.05 better than the analyst estimate of $0.80. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.18 billion.

"Hospira continues to see good momentum across our product lines, resulting in strong sales and profitability in the first half of the year," said F. Michael Ball, chief executive officer. "Complementing our strong financial performance is our continued progress on many fronts, including new generic injectable product launches, advancements in our on-market biosimilars and related pipeline, and execution of our Device Strategy. We remain committed to advancing wellness and meeting the needs of our customers and healthcare systems around the world."

NOTE: Pending merger with Pfizer (NYSE: PFE)

For earnings history and earnings-related data on Hospira (HSP) click here.

You May Also Be Interested In

• Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
• HSBC starts SpaceX at Hold, sees execution risks tempering long-term AI ambitions
• Lamb Weston (LW) Tops Q4 EPS by 25c; offers guidance